Early Diagnosis and Local Solutions Are Critical to Combat Lung Cancer

Why It Matters

Early diagnosis turns lung cancer from a near‑certain death sentence into a survivable disease, especially in low‑resource settings where health inequities are greatest.

Key Takeaways

• Lung cancer caused 1.8 million deaths in 2020.
• Early-stage detection raises 5‑year survival to ~60 %.
• Low‑dose CT screening can exceed 80 % 20‑year survival.
• Africa’s underdiagnosis linked to TB symptom overlap.
• BMS Foundation embeds screening in TB/HIV programs.

Pulse Analysis

The global lung‑cancer burden is stark: it accounts for roughly 18 % of all cancer deaths, driven not only by tobacco but also by rising air‑pollution exposure and a shift toward adenocarcinoma, which now represents nearly half of cases in men and 60 % in women. These epidemiological changes underscore the urgency of moving beyond prevention to systematic early detection, especially as high‑income nations demonstrate that survival can be dramatically improved with timely intervention.

In high‑resource settings, low‑dose computed tomography (LDCT) has become the gold standard for screening high‑risk populations, delivering five‑year survival rates near 60 % and long‑term survival exceeding 80 % when cancers are caught at an early stage. Yet in low‑ and middle‑income countries, especially sub‑Saharan Africa, diagnostic pathways are fragmented; symptoms often overlap with tuberculosis, leading to misclassification and delayed care. The lack of imaging equipment, pathology services, and trained radiologists creates a bottleneck that prevents the benefits of LDCT from reaching those who need it most.

The Bristol Myers Squibb Foundation’s Multinational Lung Cancer Control Program tackles these gaps by leveraging existing TB and HIV infrastructures. By training local clinicians, integrating referral algorithms into routine infectious‑disease visits, and establishing data registries, the program creates a sustainable diagnostic ecosystem. This model not only accelerates early case finding but also generates local evidence to inform policy and attract further investment. As these approaches prove scalable, they offer a blueprint for global health stakeholders seeking to reduce lung‑cancer mortality through equitable, data‑driven, and locally owned solutions.